Although both PD-1 inhibitors and PD-L1 inhibitors share the goal of blocking this immunosuppressive pathway to restore the immune effector activity of T lymphocytes against tumor cells, they differ in their mechanism of action, leading to pathophysiological differences with relevant clinical implications. The gene discussed is CD274; the disease is neoplasm.